U.S. Markets close in 2 hrs 30 mins
  • S&P 500

    4,583.14
    +6.03 (+0.13%)
     
  • Dow 30

    35,351.71
    -16.76 (-0.05%)
     
  • Nasdaq

    14,545.05
    +38.16 (+0.26%)
     
  • Russell 2000

    2,090.32
    -5.91 (-0.28%)
     
  • Crude Oil

    86.27
    +0.84 (+0.98%)
     
  • Gold

    1,842.10
    +29.70 (+1.64%)
     
  • Silver

    24.22
    +0.72 (+3.08%)
     
  • EUR/USD

    1.1352
    +0.0022 (+0.1930%)
     
  • 10-Yr Bond

    1.8270
    -0.0380 (-2.04%)
     
  • Vix

    22.29
    -0.50 (-2.19%)
     
  • GBP/USD

    1.3631
    +0.0033 (+0.2426%)
     
  • USD/JPY

    114.2560
    -0.3290 (-0.2871%)
     
  • BTC-USD

    42,131.93
    +639.94 (+1.54%)
     
  • CMC Crypto 200

    1,001.38
    +6.63 (+0.67%)
     
  • FTSE 100

    7,589.66
    +26.11 (+0.35%)
     
  • Nikkei 225

    27,467.23
    -790.02 (-2.80%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PT, NXTC and ICPT

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / November 18, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Pintec Technology Holdings Limited (NASDAQ:PT)
This lawsuit is on behalf of shareholders who purchased PT securities pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's October 2018 initial public offering.
Lead Plaintiff Deadline: November 30, 2020

Throughout the class period, Pintec Technology Holdings Limited allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company erroneously recorded revenue earned from certain technical service fee on a net basis, rather than a gross basis; (2) there were material weaknesses in Pintec's internal control over financial reporting related to cash advances outside the normal course of business to Jimu Group, a related party, and to a non-routine loan financing transaction with a third-party entity, Plutux Labs; (3) as a result of the foregoing, the Company's financial results for fiscal 2017 and 2018 had been misstated; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in PT: http://www.kleinstocklaw.com/pslra-1/pintec-technology-holdings-limited-loss-submission-form?id=11035&from=1

Nextcure, Inc. (NASDAQ:NXTC)
The Nextcure lawsuit was filed on behalf of investors who purchased Nextcure, Inc. (NASDAQ: NXTC) securities: (1) between November 5, 2019 and July 14, 2020, inclusive; and/or (2) pursuant or traceable to the company's secondary public offering declared effective on November 14, 2019.
Lead Plaintiff Deadline: November 20, 2020

Throughout the class period defendants' statements were materially misleading because the data Defendants possessed on its principle product candidate, NC318, showed a lack of efficacy and objective responses. Had the truth been revealed, the market would have seen that NC318 was not, in fact, effective in treating most tumor types, that the NC318 application was proving to be limited (if even useful at all), and, as a result, there was a significant realizable risk that NC318 would not be nearly as popular as then-existing blockbuster drugs, such as Keytruda.

Learn about your recoverable losses in NXTC: http://www.kleinstocklaw.com/pslra-1/nextcure-inc-loss-submission-form?id=11035&from=1

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)
Class Period: September 28, 2019 - October 7, 2020
Lead Plaintiff Deadline: January 4, 2021

During the class period, Intercept Pharmaceuticals, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Defendants downplayed the true scope and severity of safety concerns associated with the use of Ocaliva (obeticholic acid (“OCA”)), Intercept's lead product candidate, in treating primary biliary cholangitis; (ii) the foregoing increased the likelihood of a U.S. Food and Drug Administration ("FDA") investigation into Ocaliva's development, thereby jeopardizing Ocaliva's continued marketability and the sustainability of its sales; (iii) any purported benefits associated with OCA's efficacy in treating nonalcoholic steatohepatitis ("NASH") were outweighed by the risks of its use; (iv) as a result, the FDA was unlikely to approve the Company's New Drug Application for OCA in treating patients with liver fibrosis due to NASH; and (v) as a result of all the foregoing, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in ICPT: http://www.kleinstocklaw.com/pslra-1/intercept-pharmaceuticals-inc-loss-submission-form?id=11035&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/617356/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-PT-NXTC-and-ICPT